Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy.

Strobel H, Baisch T, Fitzel R, Schilberg K, Siegelin MD, Karpel-Massler G, Debatin KM, Westhoff MA.

Biomedicines. 2019 Sep 9;7(3). pii: E69. doi: 10.3390/biomedicines7030069. Review.

2.

Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?

He Y, Kaina B.

Int J Mol Sci. 2019 Mar 28;20(7). pii: E1562. doi: 10.3390/ijms20071562.

3.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
4.

Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.

Wang H, Cai S, Bailey BJ, Reza Saadatzadeh M, Ding J, Tonsing-Carter E, Georgiadis TM, Zachary Gunter T, Long EC, Minto RE, Gordon KR, Sen SE, Cai W, Eitel JA, Waning DL, Bringman LR, Wells CD, Murray ME, Sarkaria JN, Gelbert LM, Jones DR, Cohen-Gadol AA, Mayo LD, Shannon HE, Pollok KE.

J Neurosurg. 2017 Feb;126(2):446-459. doi: 10.3171/2016.1.JNS152513. Epub 2016 May 13.

5.

Dovitinib enhances temozolomide efficacy in glioblastoma cells.

Thanasupawat T, Natarajan S, Rommel A, Glogowska A, Bergen H, Krcek J, Pitz M, Beiko J, Krawitz S, Verma IM, Ghavami S, Klonisch T, Hombach-Klonisch S.

Mol Oncol. 2017 Aug;11(8):1078-1098. doi: 10.1002/1878-0261.12076. Epub 2017 Jun 5.

6.

Studies examining the synergy between Dihydrotanshinone and Temozolomide against MGMT+ glioblastoma cells in vitro: Predicting interactions with the blood-brain barrier.

Kumar V, Radin D, Leonardi D.

Biomed Pharmacother. 2019 Jan;109:386-390. doi: 10.1016/j.biopha.2018.10.069. Epub 2018 Nov 3.

7.

Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent.

Toma M, Witusik-Perkowska M, Szwed M, Stawski R, Szemraj J, Drzewiecka M, Nieborowska-Skorska M, Radek M, Kolasa P, Matlawska-Wasowska K, Sliwinski T, Skorski T.

Oncotarget. 2018 Dec 7;9(96):36867-36877. doi: 10.18632/oncotarget.26409. eCollection 2018 Dec 7.

8.

Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response.

Hombach-Klonisch S, Mehrpour M, Shojaei S, Harlos C, Pitz M, Hamai A, Siemianowicz K, Likus W, Wiechec E, Toyota BD, Hoshyar R, Seyfoori A, Sepehri Z, Ande SR, Khadem F, Akbari M, Gorman AM, Samali A, Klonisch T, Ghavami S.

Pharmacol Ther. 2018 Apr;184:13-41. doi: 10.1016/j.pharmthera.2017.10.017. Epub 2017 Nov 8. Review.

PMID:
29080702
9.

The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.

Park CK, Lee SH, Kim TM, Choi SH, Park SH, Heo DS, Kim IH, Jung HW.

J Neurooncol. 2013 Apr;112(2):277-83. doi: 10.1007/s11060-013-1060-3. Epub 2013 Feb 2.

PMID:
23377829
10.

Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent.

Chalmers AJ, Ruff EM, Martindale C, Lovegrove N, Short SC.

Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1511-9. doi: 10.1016/j.ijrobp.2009.07.1703.

PMID:
19931733
11.

Temozolomide: mechanisms of action, repair and resistance.

Zhang J, Stevens MF, Bradshaw TD.

Curr Mol Pharmacol. 2012 Jan;5(1):102-14.

PMID:
22122467
12.

Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.

Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, Aldape K, Hawkins C, Hegi M, Guha A.

J Clin Invest. 2012 Jan;122(1):253-66. doi: 10.1172/JCI59334. Epub 2011 Dec 12. Erratum in: J Clin Invest. 2012 Feb 1;122(2):782.

13.

Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.

Forte IM, Indovina P, Iannuzzi CA, Cirillo D, Di Marzo D, Barone D, Capone F, Pentimalli F, Giordano A.

Int J Oncol. 2019 Jun;54(6):2189-2199. doi: 10.3892/ijo.2019.4788. Epub 2019 Apr 16.

PMID:
31081046
14.

Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.

Kanai R, Rabkin SD, Yip S, Sgubin D, Zaupa CM, Hirose Y, Louis DN, Wakimoto H, Martuza RL.

J Natl Cancer Inst. 2012 Jan 4;104(1):42-55. doi: 10.1093/jnci/djr509. Epub 2011 Dec 15.

15.

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.

Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M.

Neurol Med Chir (Tokyo). 2018 Oct 15;58(10):405-421. doi: 10.2176/nmc.ra.2018-0141. Epub 2018 Sep 21. Review.

16.

Temozolomide resistance in glioblastoma multiforme.

Lee SY.

Genes Dis. 2016 May 11;3(3):198-210. doi: 10.1016/j.gendis.2016.04.007. eCollection 2016 Sep. Review.

17.

C1q/TNF-related peptide 8 (CTRP8) promotes temozolomide resistance in human glioblastoma.

Thanasupawat T, Glogowska A, Burg M, Krcek J, Beiko J, Pitz M, Zhang GJ, Hombach-Klonisch S, Klonisch T.

Mol Oncol. 2018 Sep;12(9):1464-1479. doi: 10.1002/1878-0261.12349. Epub 2018 Aug 2.

18.

Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.

Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF, Mitchell L, Trivedi RN, Tang JB, Sobol RW.

Cancer Res. 2011 Mar 15;71(6):2308-17. doi: 10.1158/0008-5472.CAN-10-3213.

19.

Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.

Stritzelberger J, Distel L, Buslei R, Fietkau R, Putz F.

Clin Transl Oncol. 2018 Apr;20(4):508-516. doi: 10.1007/s12094-017-1743-x. Epub 2017 Aug 20.

PMID:
28825189
20.

Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.

Tiek DM, Rone JD, Graham GT, Pannkuk EL, Haddad BR, Riggins RB.

Sci Rep. 2018 May 8;8(1):7222. doi: 10.1038/s41598-018-25588-1.

Supplemental Content

Support Center